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Abstract Bone research is limited by the methods avail-
able for detecting changes in bone metabolism. While dual
X-ray absorptiometry is rather insensitive, biochemical
markers are subject to significant intra-individual variation.
In the study presented here, we evaluated the isotopic
labeling of bone using 41Ca, a long-lived radiotracer, as an
alternative approach. After successful labeling of the
skeleton, changes in the systematics of urinary 41Ca
excretion are expected to directly reflect changes in bone
Ca metabolism. A minute amount of 41Ca (100 nCi) was
administered orally to 22 postmenopausal women. Kinetics
of tracer excretion were assessed by monitoring changes in
urinary 41Ca/40Ca isotope ratios up to 700 days post-dosing
using accelerator mass spectrometry and resonance ioniza-
tion mass spectrometry. Isotopic labeling of the skeleton
was evaluated by two different approaches: (i) urinary 41Ca
data were fitted to an established function consisting of an
exponential term and a power law term for each individual;
(ii) 41Ca data were analyzed by population pharmacokinetic
(NONMEM) analysis to identify a compartmental model
that describes urinary 41Ca tracer kinetics. A linear three-
compartment model with a central compartment and two
sequential peripheral compartments was found to best fit
the 41Ca data. Fits based on the use of the combined
exponential/power law function describing urinary tracer
excretion showed substantially higher deviations between
predicted and measured values than fits based on the
compartmental modeling approach. By establishing the
urinary 41Ca excretion pattern using data points up to day
500 and extrapolating these curves up to day 700, it was
found that the calculated 41Ca/40Ca isotope ratios in urine
were significantly lower than the observed 41Ca/40Ca
isotope ratios for both techniques. Compartmental analysis
can overcome this limitation. By identifying relative
changes in transfer rates between compartments in re-
sponse to an intervention, inaccuracies in the underlying
model cancel out. Changes in tracer distribution between
compartments were modeled based on identified kinetic
parameters. While changes in bone formation and resorp-
tion can, in principle, be assessed by monitoring urinary
41Ca excretion over the first few weeks post-dosing,
assessment of an intervention effect is more reliable
∼150 days post-dosing when excreted tracer originates
mainly from bone.
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Introduction
Age-related osteoporosis has become a major public health
concern due to the mean increase in life expectancy of three
years per decade over the last century, a trend that seems set
to continue [1]. With increasing age, bone balance becomes
increasingly negative and bone becomes brittle [2]. The
elderly face a significant increase in fracture risk, particu-
larly of the spine, hip and wrist. Apart from a serious
negative effect on individual welfare, the financial costs of
osteoporosis are enormous. Annual total direct hospital
costs arising from hip fractures alone amounted to nearly
four billion euros within the European Union in 1996, and
costs are expected to rise significantly [3].
A more detailed understanding of Ca metabolism in
bone would help to better define the diet and life-style
strategies needed for osteoporosis prevention. At present,
no methodologies exist that allow the measurement of
small changes in bone metabolism directly, with high
sensitivity and on a short-term scale. Such small short-
term changes in bone metabolism can result from
alterations in diet and lifestyle. These changes accumulate
with time and may play a significant role in maintaining
bone health.
Alterations in bone Ca metabolism can be followed by
monitoring changes in bone mineral density (BMD) with
dual energy X-ray absorptiometry (DXA). The precision of
conventional DXA machines is on the order of 1–2%,
depending on the site measured [4, 5]. This limits the
potential of DXA for the evaluation of the small changes in
bone metabolism that can be expected from nutritional
interventions and life-style changes. Changes in bone
metabolism can also be monitored indirectly using bio-
chemical markers of bone metabolism. Bone resorption can
be assessed by measuring bone collagen degradation
products in urine, while bone accretion can be monitored
by measuring bone-specific proteins or enzymes in blood
[6]. These biomarkers, however, are subject to strong intra-
individual variations. Typical within-subject variations in
biomarker concentration are on the order of 10–45% for
bone resorption markers in urine and 5–10% for bone
formation markers in serum [7], thus limiting the sensitivity
of these tests. In addition, biomarkers of bone resorption
and accretion are independent measures and cannot be
combined to assess bone balance.
Isotopic techniques could overcome the current limita-
tions of the existing techniques for monitoring bone
metabolism. Changes in skeletal Ca metabolism can be
determined directly by Ca kinetic studies involving oral and
intravenous administration of stable or radioactive Ca
isotopes and by monitoring tracer appearance and disap-
pearance in blood, urine and feces over 10–15 days.
Although this technique reveals changes in bone accretion
and resorption rates in response to an intervention, it is
invasive and costly and difficult to apply to large subject
groups. As Ca turnover in bone is slow, bone Ca can be
labeled in vivo by administering Ca isotope tracers.
Following administration, tracer not incorporated into the
bone matrix is gradually excreted from the body in urine.
After the excess tracer in the dosing compartment has been
eliminated, the tracer in urine originates mainly from Ca
incorporated into bone, and changes in bone metabolism
can thus be assessed via the observed changes in urinary
tracer excretion. However, the costs of bone labeling would
be prohibitively high using stable Ca isotope labels, and it
is not possible to use conventional Ca radiotracers because
of ethical considerations about radiating the bone marrow.
A potent alternative is 41Ca, a virtually stable, very long-
lived radioisotope (half-life: 104,000 years) which can be
detected at the ultratrace level using accelerator mass
spectrometry (AMS) [8] or by resonance ionization mass
spectrometry (RIMS) [9]. Conventional mass spectrometric
techniques such as thermal ionization mass spectrometry
(TIMS) or inductively coupled plasma mass spectrometry
(ICP–MS) are not sensitive enough for this purpose. Even
for high-resolution instruments, the abundance sensitivity is
much too low to effectively suppress contributions to the
41Ca signal by neighboring peaks. Doses would have to be
increased substantially to overcome limits on abundance
sensitivity. This would jeopardize the main advantage of
using 41Ca as a tracer, which is still a radioisotope despite
its long half-life. Bone can be labeled at negligible health
risk using AMS or RIMS for 41Ca analysis, because only
minute amounts of the tracer have to be administered.
The feasibility of using 41Ca in bone research has been
demonstrated by Johnson and coworkers, who labeled the
skeleton of a single human subject with 41Ca and followed
urinary 41Ca excretion over more than a year using AMS
[10]. Also, in a human study, it was demonstrated more
recently that the urinary 41Ca signal changes in response to
bisphosphonate administration, a potent drug known to
inhibit bone resorption [11]. Most recently, the serum
41Ca/40Ca signal demonstrated significant differences be-
tween four healthy individuals and four end-stage renal
failure patients [12].
When assessing changes in bone Ca metabolism in
response to an intervention, the kinetics of urinary 41Ca
excretion first need to be established for the individual. The
Ca excretion pattern can be described mathematically using
nonlinear curve-fitting techniques [13]. This so-called
labeling curve can serve as a fixed index from which
changes due to the intervention can be assessed (see Fig. 1).
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The effect of an intervention can be evaluated by
calculating the change in the tracer signal during the
intervention relative to the extrapolation from the labeling
curve. In addition, compartmental modeling techniques can
be applied for data evaluation. Techniques applied to study
short-term Ca kinetics in humans closely follow well-
established concepts [14]. It was demonstrated in an earlier
experiment that the kinetics of 41Ca in the human body can
be described by applying compartmental modeling tech-
niques [10]. In our studies, a compartmental model that
describes the observed 41Ca excretion pattern in urine was
established via pharmacokinetic modeling techniques. By
fitting the proposed model to observed data by nonlinear
mixed-effects regression analysis, the effect of an interven-
tion can be identified in the form of changes to the transfer
rates of 41Ca between different Ca compartments.
Earlier experiments in human subjects have shown that,
in principle, Ca in the human skeleton can be labeled using
41Ca, and that changes in bone Ca metabolism can be
assessed to a much higher sensitivity than by any
established technique. To make use of this technique in
biomedical research, however, kinetics of urinary 41Ca
excretion must be firmly established and evaluated, taking
into account variations between subjects. The aim of the
present study was to demonstrate the feasibility of using
41Ca to isotopically label bone and to describe mathemat-
ically the urinary excretion pattern of the 41Ca tracer after a
single oral administration. We therefore administered 41Ca
to 25 postmenopausal women and followed urinary 41Ca
excretion at regular intervals for up to two years by AMS
and RIMS. An integral part of this study was the production
(by the EC Joint Research Centre, Institute for Reference
Materials and Measurements; IRMM) of a standardized
dose material (IRMM-3703) and a set of certified 41Ca
isotopic reference materials (IRMM-3701) for calibrating
the various techniques used for 41Ca analysis against each
other [15]. Tracer excretion was evaluated by nonlinear
curve fitting and compartmental modeling techniques,
including the identification of the most suitable model for
describing long-term kinetics of 41Ca elimination in
humans. Concepts for data collection and evaluation in
human studies are proposed that may serve as the basis for
further applications of this promising new technique.
Experimental
Subjects
Twenty-five apparently healthy women, at least five years
postmenopausal, were recruited from a program for elderly
citizens at the University of Zurich, Switzerland, and
through advertisements in a local newspaper. All subjects
were of Caucasian descent. None of the subjects had any
known systemic disease or were taking any medication or
dietary supplements that could potentially influence Ca
homeostasis or bone status, including Ca, vitamin D,
bisphosphonates, estrogens and diuretics. In order to
exclude subjects with osteoporosis, a bone mineral density
(BMD) scan was performed by DXA (Hologic QDR-
4500A, Hologic Inc., Bedford, MA, USA) at a local
hospital. Dietary Ca intake was assessed at the beginning
of the study by a standardized food frequency questionnaire
adapted for Swiss products and evaluated using the Swiss
food composition database. The study protocol was
approved by the Ethical Committee of the Swiss Federal
Labeling period Intervention Placebo
Labeling curve
Change
Days after 41Ca administration
Urinary
41Ca
signal
Fig. 1 Basic principle behind
the use of 41Ca to monitor
changes in bone metabolism.
After administration of the iso-
tope, the urinary excretion pat-
tern of the tracer is followed
during the labeling period. This
so-called labeling curve serves
as an unchanging index from
which perturbations due to
interventions can be assessed
once steady-state kinetics for
41Ca are established, i.e. when
all of the 41Ca that is recovered
in urine was previously incor-
porated into bone
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Institute of Technology, Zurich. Subjects were informed
orally and in writing. Written informed consent was
obtained from all volunteers. Subjects were asked to refrain
from any medication that could potentially affect bone or
cartilage metabolism and from the intake of vitamin and
mineral supplements during the entire study. Compliance
was monitored by regular interviews.
Study protocol
Subjects received a single oral dose of 3.7 kBq (100 nCi;
2.823×10−5 mmol) 41Ca as an aqueous solution together
with a standardized light breakfast (toast, butter and jam)
after an overnight fast on day 1 of the study. The drink
consisted of 300.0 ml ultrapure (18 MΩ) water to which the
41Ca solution had been added (2.00 ml). No food or fluids
were allowed for three hours after test meal intake.
Excretion of 41Ca was monitored in 24 h urine collections
to establish the kinetics of urinary clearance for the isotopic
label. Urine samples were collected at two, four, six and
eight weeks after isotope administration, and then at
monthly intervals for up to two years. Urine was collected
in preweighed 2 L polyethylene bottles containing 10 ml
1 M HNO3 (p.a.) in order to minimize precipitation during
storage. The weights of the HNO3 plus 24 h urine
collections were recorded. At an average Ca amount of
∼300 mg per 24 h urine collection, sampling blanks were
negligible. In order to avoid seasonal variations in vitamin
D status, subjects were supplemented throughout the entire
study with 10 μg vitamin D (Dekristol, 10 μg cholecalcif-
erol per capsule, Jenapharm AG, Jena, Germany) per day,
commencing on the day of 41Ca administration. Compli-
ance was monitored via self-reported intake and cross-
checked by pill counts every month. Diet was unrestricted
but subjects were requested to maintain their dietary habits
or lifestyle, in particular their physical activity, over the
course of the entire study.
41Ca dose material
The 41Ca source material used in this work was produced
about 20 years ago at Oak Ridge National Laboratory
(ORNL, Oak Ridge, TN, USA) by neutron activation of
stable 40Ca (CaO), which was enriched to >99.998%, for
three years. The activated material was run through an
electromagnetic isotope separation (EMIS) process for 41Ca
enrichment. Enrichment of the source material was 1.33%
at the time of production [15]. A solution of this material
with a nominal 41Ca/40Ca ratio of 1% was made available
to IRMM by Argonne National Laboratory (ANL,
Argonne, IL, USA) and Purdue Rare Isotope Measurement
Laboratory (West Lafayette, IN, USA). Production and
certification of the isotopic reference materials and the dose
material at IRMM followed the requirements set out in ISO
Guide 35 and are described in detail by [15]. The solution
was first monitored at high sensitivity for gamma-ray
emitting impurities using underground gamma-ray spec-
trometry in a 225 m-deep laboratory [16], and a certificate
was issued. No significant radiocontaminants were found. It
was then purified by precipitation of Ni as nickel NiS, and
the purified solution, to be used as a dose material, was
labeled IRMM-3703. Concentration levels of other metal
impurities are available from IRMM [17].
An aliquot of 1.5 g of IRMM-3703 was gravimetrically
diluted with a solution of high-purity HCl and aliquots,
labeled IM-6010, were stored in sealed quartz ampoules.
IM-6010 and IRMM-3703 were certified for Ca isotopic
composition and IM-6010 was certified for Ca amount
content by isotope dilution mass spectrometry on IM-6010,
using a 44Ca-enriched isotopic reference material
(IM-6009) as spike and the natural Ca reference material
IM-6008 for k-factor determination. Isotope ratio measure-
ments were performed using a double-filament technique on
a modified single-sector Finnigan-MAT 260 thermal ioniza-
tion mass spectrometer (TIMS, Finnigan MAT, Bremen,
Germany). Measured 41Ca/40Ca isotope ratios were cor-
rected for residual 41K by applying a factor based on the
39K/40K ratio measured during the same scan. Table 1
shows the certified isotopic composition of the dose
material IRMM-3703.
Separation of Ca from urine for isotopic analysis
Ca was separated from collected urines for 41Ca analysis by
oxalate precipitation at the Human Nutrition Laboratory,
ETH Zurich, using established procedures [18]. One aliquot
of 30.0 ml was taken from each 24-h urine sample.
Separated calcium was analyzed at least in duplicate for
41Ca by AMS or RIMS. For Ca separation, sample pH was
adjusted to 10 by addition of ammonium hydroxide and
60 ml of a saturated aqueous ammonium oxalate solution
were added. Samples were heated to 70 °C followed by
immersion into an ice bath for 90 min. Precipitates were
separated by centrifugation and the supernatant was
Table 1 Isotopic composition of the 41Ca dose material, IRMM-3703
Isotopic ratio Certified value
41Ca/40Ca 0.012789(58)
42Ca/40Ca 0.0037979(96)
43Ca/40Ca 0.000390(11)
44Ca/40Ca 0.005750(18)
46Ca/40Ca 0.0000135(21)
48Ca/40Ca 0.0005268(80)
Uncertainties are given as expanded uncertainties (k=2) and apply to
the last two digits of the value.
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removed. Precipitates were washed twice with 40 ml of
saturated ammonium oxalate solution, followed by centri-
fugation and removal of the supernatant. To remove K and
Na impurities, the precipitate was washed with 40 ml of a
0.1% (w/v) ammonium oxalate solution. In addition, Ca
solutions were purified by ion exchange chromatography
(AG50W-X8, Bio-Rad Laboratories, Hercules, CA, USA)
using disposable columns. Purified solutions were trans-
ferred to a quartz beaker, covered with a quartz lid and dried
overnight at 90 °C in an oven. Dried precipitates were ashed
for 1 h in a muffle furnace at 1000 °C to remove traces of
organic matter by which the Ca oxalate could be transformed
into CaO. Ca recovery was >95% for the overall process. Ca
separation was carried out following the principles of trace
element analysis in order to reduce the risk of sample
contamination. Only chemicals of analytical grade quality
and ultrapure water (18 MΩ) was used. Acids were purified
by subboiling distillation. Labware was acid-washed and
samples were handled under laminar flow conditions under
constant separation blank monitoring.
Isotopic analysis
n(41Ca)/n(40Ca) isotope amount ratios (hereafter referred to
as 41Ca/40Ca isotope ratios) were monitored in the collected
urine samples up to 700 days after isotope administration.
Due to restricted access to the AMS and RIMS machines,
subjects were organized into four subgroups (A, B, C, D),
which differed in the length of the monitoring period, the
number of urine samples collected and analyzed and the
analytical facilities used. The six subjects of subgroup A
collected urine samples for ∼700 days, and urine samples
were analyzed for 41Ca at 20–30 time points per subject by
AMS at Lawrence Livermore National Laboratory. Urinary
41Ca/40Ca isotope ratios were monitored in subgroup B
(n=4) over a period of ∼400 days at 10–12 time points.
Urine samples from this subgroup from the early phase of
the study (<150 d after tracer administration) were analyzed
by RIMS at the University of Mainz, while samples from
the later phase (>150 days after tracer administration) were
analyzed by AMS at ETH Zurich. For the eight subjects in
subgroup C, urinary 41Ca/40Ca isotope ratios were deter-
mined at 7–8 time points covering a period of up to
260 days after isotope administration by AMS at ETH
Zurich. For the three subjects in subgroup D, 41Ca/40Ca
isotope ratios were determined by AMS at ETH Zurich in
2–3 selected urine samples which were collected over a
period of about 240 days (see Table 3).
41Ca isotopic analysis by AMS (ETH Zurich)
Ca separated from urine delivered as CaO (∼10 mg Ca per
sample) was converted to CaH2 as the target material for
AMS analysis. Isolated CaO was mixed with Zr and heated
under high vacuum by electron bombardment and distilled
to transform the sample into Ca metal [19]. Typical
distillation yields were on the order of 85%. Ca metal was
converted into its hydride by heating the metal under a
hydrogen atmosphere at ∼640 °C (hydration yield: 70–
100%). The hygroscopic CaH2 samples obtained were
pressed into Cu cathodes and stored under vacuum until
the AMS measurement.
Samples were analyzed for 41Ca using the PSI/ETH 6
MV tandem AMS facility. The experimental set-up is
described in detail elsewhere [19]. CaH2 targets were
sputtered with Cs+ ions, and negative ions were extracted
from the ion source. The ion beam was mass-analyzed and
particles of mass-to-charge ratio 44 (41CaH3
− ions) were
injected into the accelerator. Electrons were removed from
separated ions by gas stripping. Ions of charge state 4+
were selected to filter out molecular ions and to minimize
parasitic O2+ and S4+ beams that render measurements of
40Ca ion beams difficult.
Measurements were performed at a terminal voltage of
5 MV. Typical ion currents of CaH3
− were 400 nA for
prepared samples and 800 nA for blanks and secondary
standards made from commercially available CaH2. Trans-
missions ranged from 10 to 16%. Particles were identified
with a three-anode ionization chamber. A time-of-flight
spectrometer was used to improve mass separation, in
particular for efficient suppression of 42CaH2
4+ ions.
Reported data are normalized to IRMM-3701. 41Ca/40Ca
ratios for chemical and instrumental blanks were 1–2×10−13.
Average repeatability (1 SD) of independent isotope ratio
measurements (n=5) was 2.2%, with 90% of the data
having a repeatability of <3.5%.
41Ca isotopic analysis by AMS (Lawrence Livermore
National Laboratory)
Sample processing and measurement followed established
procedures [18, 20, 21] with minor modifications. Chem-
icals were all of analytical grade, water was distilled and
deionized, and all labware was single-use. CaO samples
were dissolved in 1 ml 5 N HNO3 and brought up to
50 ml with water. Sample Ca solutions were loaded into
resin beds previously prepared by rinsing sequentially
with 10 ml of water, 5 N HNO3, water and 0.08 N HNO3,
respectively. After sample loading, the resin beds were
rinsed with 10 ml 0.08 N HNO3. Sample Ca was eluted
using 6 ml 5 N HNO3 and passed through the resin in three
equal aliquots of 2 ml.
Solution pH was adjusted to produce a solution of
∼0.5 M H+ through the addition of 1.5 ml of concentrated
ammonium hydroxide, and after thorough mixing 2–3 ml of
48% HF was added. After at least 12 hours, the sample
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CaF2 was isolated via centrifugation, washed with 0.01 N
HF, and dried overnight in a muffle furnace at 90 °C.
The CaF2 prepared was mixed with silver powder
(4 parts CaF2 : 1 part Ag by mass) and pressed into
aluminum AMS sample holders. Samples and concurrently
produced standards and blanks were placed in the AMS ion
source. 41Ca/40Ca isotope ratios were measured in samples,
standards and blanks as follows: (1) mass separation of
CaF3
− molecules; (2) acceleration of these molecules
through 9.1 million volts; (3) removal of nine electrons
through charge exchange in a thin carbon foil at the high-
voltage terminal; (4) a second acceleration to ground
potential (final energy >76 MeV); (5) measurement of
40Ca8+ in an offset Faraday cup after mass analysis; (6) ion
identification and single particle counting of 41Ca8+ in a
multi-anode gas ionization detector after additional mass
and velocity filters. Raw ratios of 41Ca8+ counts (collected
for 100–200 s) to total 40Ca8+ charge (collected in 50 μs
pulses at ∼3 Hz) were calculated by the data collection
system. Samples and standards were run at least four
times, and final 41Ca/Ca was calculated via normalization
to the known standard ratios, and assuming natural 40Ca
abundance [22].
The unweighted average chemistry blank was 41Ca Ca ¼
1:5 0:9ð Þ  1013 for samples with 41Ca/Ca<10−8; above
this level, minor ion source memory from high-41Ca
samples produced a slightly higher background of (2.2±
0.5)×10−12. The certified isotope reference materials
IRMM-3701/4, /5, and /6 (Table 2) were each measured
in triplicate, and AMS results were scattered around known
values at a 1 SD reproducibility averaging 3–5% for the
different standards. Because of an observed nonlinearity for
IRMM-3701/3 (41Ca/40Ca=10−8), the minimum uncertainty
for samples with a 41Ca/40Ca isotope ratio higher than
5×10−9 was set to 10%.
41Ca isotopic analysis by RIMS (University of Mainz)
Ca separated from urine as CaO at the Laboratory of
Human Nutrition, ETH Zurich, was dissolved in 1 ml 3M
nitric acid and stored in solution. For analysis, about 10 μl
of the Ca(NO3)2 solution was brought onto a Ta carrier foil,
dried at ∼90 °C under normal pressure, and inserted into a
graphite furnace. The oven was introduced into a small
high-vacuum chamber via a fast vacuum lock and Ca was
reduced and atomized to form an atomic beam at temper-
atures of around 1600 °C. Selective ionization was carried
out by resonant optical excitation using a system of three
commercial continuous diode lasers (Model DL100, TUI
Optics GmbH, Gräfeling, Germany). For the first excitation
step, red diode laser light was converted into the blue
spectral region by a custom-designed frequency doubling
unit. Selectively excited Ca atoms were ionized by a CO2
laser (48-2W, EXCEL Technology Europe GmbH, Fürsten-
feldbruck, Germany) and mass-analyzed using a quadru-
pole mass spectrometer (QMS, MEXM64, ABB Extrel,
Pittsburgh, PA, USA). The exact amount of transferred
isotopic label was determined by reweighing the glass vials.
Quantitative low-background ion detection was carried out
by a channeltron (402A-H, De Tech, Palmer, MA, USA).
To determine the Ca isotope ratios, the laser and QMS
were tuned alternately to different resonance positions and
count rates were taken. Specifications for an overall
efficiency of >10−5, with a relative limit of detection of
2×10−13 for the 41Ca/40Ca ratio, and with a repeatability of
about 5%, had been demonstrated previously [23].
41Ca reference material
To calibrate the different mass spectrometric techniques
against each other, a series of isotopic reference materials
for 41Ca (IRMM-3701) was produced and certified for
isotope amount ratios [15]. The IRMM-3701 series covers a
range of 41Ca/40Ca isotope amount ratios from 10−6 to
10−13 (Table 2). It is derived from the gravimetric mixing of
a 41Ca solution (IM-6010), which was certified for Ca
amount content and isotopic composition, and a Ca solution
prepared from CaCO3 (99.95% purity, Merck, Darmstadt,
Germany) of natural isotopic composition. The 41Ca/40Ca
isotope amount ratio of the CaCO3, as measured by AMS,
was below the limit of detection (5×10−14). The 41Ca/40Ca
isotope amount ratios of the series have been measured
independently by AMS and RIMS over the total range.
Linearity was excellent for both techniques [15]. The RIMS
measurements presented were normalized to IRMM-3701
to ensure the comparability of the 41Ca data generated.
For the AMS measurements, concurrent check standards
were prepared. The AMS data matched the IRMM-3701
standards within the measurement uncertainty.
Table 2 Certified isotope amount ratios of the IRMM-3701 isotope
reference materials used in this study to calibrate AMS and RIMS
measurements against each other
Isotopic reference material n(41Ca)/n(40Ca)
IRMM-3701/1 1.011 4(68)×10−6
IRMM-3701/2 1.023 5(69)×10−7
IRMM-3701/3 1.018 1(69)×10−8
IRMM-3701/4 1.047 9(71)×10−9
IRMM-3701/5 1.052 0(71)×10−10
IRMM-3701/6 1.091 3(74)×10−11
IRMM-3701/7 1.054 9(72)×10−12
IRMM-3701/8 1.052 4(71)×10−13
Uncertainties are given as expanded uncertainties (k=2) and apply to
the last two digits of the value.
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Total calcium analysis
Total Ca was determined directly in urine samples at the
Laboratory of Human Nutrition, ETH Zurich, by flame
atomic absorption spectrometry (SpectrAA 400, Mulgrave,
Australia) in an air/acetylene flame after appropriate
dilution (1:20 to 1:50) with an acidified 0.5% (w/v)
lanthanum chloride solution. A commercial aqueous
standard (Titrisol, Merck, Darmstadt, Germany) was used
for internal standard addition. Quality control material was
processed in parallel with urine (Lyphocheck, Quantitative
Urine Control, BioRad, Anaheim, CA, USA). Ca analysis of
the test meal was performed using the standard addition
technique after microwave digestion using a HNO3/H2O2
mixture. The average repeatability was 3.5% RSD for
independent runs of the same samples.
Urinary 41Ca excretion pattern
Combined power/exponential law analysis The retention
systematics of bone-seeking elements such as Ca were
investigated earlier using radioisotopic techniques and
described by a combined power/exponential law [13, 24].
This analysis arose in the 1960s and early 1970s, when
researchers had limited computer access and thus sought
“simpler and computationally more tractable models [that]
can be formulated using other mathematical functions, such
as power functions” [25]. As the urinary excretion of an
administered Ca tracer over time is a derivate of retention, it
can be described by
E tð Þ ¼ A  tB þ C  eDt ð1Þ
where E(t) is the Ca amount or concentration in urine and A,
B, C and D are parameters reflecting individual differences
in urinary tracer excretion. The individual parameters A, B, C
and D were determined for each subject by fitting the curve
described by Eq. 1 to observed 41Ca data in urine. Data were
analyzed using commercial software (Origin 7, OriginLab
Corporation, Northampton, MA, USA). Analytical errors (σ)
in the individual data points were taken into account by
weighting data points for measurement precision (w=1/σ2).
Population pharmacokinetic analysis In parallel with the
combined power/exponential fitting procedures described
above, data were also fitted to several compartmental
models using population pharmacokinetics. If compartmen-
tal models are used, it can be assumed that a drug or any
other compound, such as an isotopic tracer administered to
the human body, distributes and exchanges between a series
of compartments [26]. These compartments may, but do not
have to, represent anatomic spaces such as organs or body
tissues. The concentrations of the tracer in plasma, urine
and/or feces over the time of the study will thus depend on
the transfer rates between compartments and the compart-
ment volumes. Accordingly, transfer rates and compartment
volumes represent the parameters Pi to be estimated based
on the observed concentration data yij, i.e.:
yij ¼ f tij;Pi
   e"1ij þ "2ij ð2Þ
where f represents the function describing the compartmen-
tal model, evaluated at time tij for subject i studied at time j,
whereas ɛ1ij and ɛ2ij represent the heteroscedastic and
homoscedastic residual variabilities, which cover analytical
error, within-subject variability and model misspecification.
In population pharmacokinetics, the parameters of subject i,
Pi, are in turn expressed as
Pi ¼ g q; Zið Þ þ hi ð3Þ
where g is a function of θ, a vector of unknown parameters
assumed to have the same value in each subject (the fixed
effects), Z is the subject’s characteristics (e.g., age, body
weight), and η is a vector of unknown parameters belonging
to subject i (the random effects). The parameter η is
assumed to be multivariate and normally distributed with a
mean of 0 and with variances to be estimated [27–29]. To
do so, the data on urinary 41Ca excretion from the 22 study
participants were combined into one data set, and fit jointly
to the different compartmental models using the first-order
method (FO) of the commercial Nonlinear Mixed Effects
Modeling Method Software (NONMEM, version V, run-
ning with NM-TRAN version II, University of California,
San Francisco, CA, USA). The statistical model accounting
for intra-individual variability consisted of an exponential
error and an additive error term (see Eq. 2). We thus used
maximum likelihood (ML) for curve fitting and mixed-
effects regression (fixed and random) to estimate popula-
tion means and variances of kinetic parameters (NONMEM
Users Guides, University of California, San Francisco, CA,
USA). Furthermore, the POSTHOC option was applied to
obtain individual parameter estimates and individual con-
centration predictions after the analysis.
A stepwise procedure was used to identify the model that
describes the experimental data best. There are three
different criteria used to compare the different models: the
Schwarz information criterion (BIC), the Akaike criterion
(AIC) or the Hannan–Quinn criterion (HQ). It has been
shown, however, that the BIC is the most conservative
criterion of these three [30], and it was therefore selected as
the most appropriate tool to avoid overfitting of the data.
The BIC depends on the objective function OF, the overall
number p of (fixed and random effect) parameters to be
estimated, and the number of data points N in the dataset.
BIC ¼ OF þ p  log Nð Þ ð4Þ
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where the OF corresponds to minus twice the logarithm of the
likelihood, and can be directly obtained from the NONMEM
output [31]. Thus, the BIC favors models which describe the
data appropriately, i.e., that exhibit the lowest OF, and also
take into account the number of parameters in order to avoid
overfitting of the data. For models with rather small BIC
differences, we compared interindividual variability estimates,
intraindividual variability estimates, normalized root mean
square errors (NRMSE) and normalized mean error (NME) of
the differences between measurements and predictions.
The 41Ca/40Ca isotope ratio was chosen for data evalua-
tion. Because of the high natural abundance of 40Ca of
96.941% [32], it can be regarded as a proxy for the 41Ca/Ca
ratio. To calculate the kinetic parameters, the initial dose of
41Ca entering compartment 1 and the concentration of 41Ca
in this compartment over the 700-day monitoring period
were required. As these variables could not be directly
measured in the study, they had to be set to reasonable a
priori guesses. As the 41Ca dose was administered orally, an
assumption for the bioavailability had to be made in order to
assess the amount of tracer transferred from the intestine into
compartment 1 to estimate an “iv proxy dose.” An absorption
efficiency of 50% was assumed, as we observed from a
recent study on the same subjects that Ca absorption from a
similar standardized test meal was 51.2±8.9% (Denk E,
Walczyk T, Hurrell RF, manuscript in preparation). At an oral
41Ca dose of 2.35×10−5 mmol, this results into an “iv proxy
dose” of 1.18×10−5 mmol. It is not expected that variations in
Ca absorption efficiency have any influence on the outcome
of the model-finding procedure, since any possible difference
between the assumed and actual dose of the tracer reaching
the systemic circulation would just shift the urinary 41Ca
excretion pattern up or down. The shape of the curve, which
determines the kinetic model, would not be changed. Such a
difference would induce at most a change in the pool size of
compartment one (V1) and thus any derived absolute transfer
rates in mg Ca per day, respectively. For this reason, transfer
rates are given in relative and not in absolute terms.
In order to assess changes in the 41Ca concentration in
compartment 1 over time, the urinary 41Ca/40Ca isotope
ratios had to be transformed into 41Ca concentrations in
plasma. Physiologically, compartment 1 probably corre-
sponds to Ca in extracellular fluids (ECF) and the cellular
pool. In the ECF and in the cellular compartment, the
concentration of ionized Ca is maintained within the narrow
range of 1.15–1.25 mmol/l [33]. As discussed before, urinary
41Ca/40Ca isotope ratios can be regarded as substitutes for
the 41Ca/40Ca isotope ratios in plasma. Therefore, urinary
41Ca/40Ca isotope ratios could be transformed into 41Ca
concentrations in plasma based on a mean concentration for
plasma Ca of 1.2 mmol/l. Based on the calculated 41Ca “iv
proxy dose” and the 41Ca concentration in compartment 1,
the kinetic parameters of the final model were obtained.
Results and discussion
Subject characteristics
Three out of the 25 subjects did not complete the study. One
subject had to be excluded from the study due to illness.
Another subject experienced a fracture. A third subject died
of other causes during the study. Data from the three subjects
were excluded from all analyses. The remaining 22 subjects
were 66.7±4.9 years at the beginning of the study and had a
mean body mass index of 26.1±3.3 kg/m2. Mean Ca intake
assessed by food frequency questionnaire was 803±257 mg
Ca per day and BMD was −1.48±0.72 (T-score in femur
neck) at the beginning of the study.
Assessment of urinary 41Ca excretion
In order to assess the biological variability of the 41Ca
signal, 24-h urine samples of four subjects of subgroup B
were collected on four consecutive days after a labeling
period of 240 days. Significant variations in the daily
amount of excreted 41Ca were observed in each individual
(RSD: 26.3–36.3%), as derived from the urinary 41Ca/40Ca
isotope ratio and the Ca amount excreted in urine. As
expected, daily urinary Ca losses showed significant intra-
individual variations (RSD: 28.3–36.2%). Intra-individual
variations, however, were much smaller for the urinary
41Ca/40Ca isotope ratio (RSD: 2.2–4.3%), see Fig. 2.
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Fig. 2 Variations in the urinary 41Ca/40Ca isotope ratio (full symbols)
and the total amount of 41Ca (open symbols) on four consecutive days,
as observed in the 24-h urine samples collected. Data are plotted as the
relative deviation from the mean over all four urine samples from the
same subject
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Although urinary Ca losses varied strongly between
days, this did not affect the urinary 41Ca/40Ca isotope ratio
significantly. This is in agreement with basic principles of
human Ca metabolism. Ca in plasma is effectively
reabsorbed in the kidneys and only a small fraction passing
through the kidneys (<1%) is inevitably lost in urine. This
fraction can vary significantly in the individual within and
between days, depending on diet and lifestyle factors [34].
Because the human body cannot distinguish between Ca
isotopes within the measurement errors of the applied
techniques, it can be assumed that equal fractions of natural
Ca and 41Ca are transferred from plasma into urine. The
urinary 41Ca/40Ca isotope ratio thus becomes a direct
measure of the isotopic composition of plasma Ca, which
is more stable than the 41Ca amount excreted in urine. This
has been confirmed recently [21], and makes the urinary
41Ca/40Ca isotope ratio the measure of choice for monitor-
ing changes in bone Ca metabolism. Because Ca concen-
tration in plasma is subject to close homeostasis within a
narrow range, and plasma volume likewise shows only
small variations, the amount of circulating natural Ca in
plasma is highly constant in the individual. Thus, changes
in the urinary 41Ca/40Ca isotope ratio directly reflect
changes in 41Ca concentration as well as changes in the
circulating 41Ca amount in plasma.
Kinetics of urinary 41Ca excretion
Combined power/exponential analysis
In the era before readily available computing power, the
systematics of urinary 41Ca excretion were described by a
function consisting of an exponential term and a power term
(see Eq. 1). For subjects from subgroups A, B and C, enough
data points were available to fit parameters in Eq. 1 to the
observed data points. For subjects in subgroup D, analysis
was limited to 2–3 samples per individual, which is not
sufficient to solve Eq. 1. According to [13], the exponential
term of the function becomes negligible at intervals greater
than 30 days after dose administration, and so labeling
curves can be described by the power term alone after that:
E tð Þ ¼ A  tB ð5Þ
By using Eq. 5, labeling curves were established for three
subjects (subgroup D) using the three data points obtained
within the later part of the labeling phase (>150 days).
Calculated parameters describing the changes in the urinary
41Ca/40Ca isotope ratio according to Eqs. 1 and 5 are given
in Table 3. The data obtained for tracer excretion from all
subjects are plotted in Fig. 4. From the data presented in
Table 3, it is apparent that urinary tracer excretion can be
Table 3 Parameters describing changes in urinary 41Ca/40Ca isotope ratios with time based on a combined power/exponential law
E tð Þ ¼ AtB þ CeDtð Þ
Subgroup Subject ID No. of measurements R2 A B C D
A 1 31 0.969 27.10(76)×10−9 −0.8249(52) 49.11(42)×10−9 −0.09253(45)
2 28 0.982 22.40(83)×10−9 −0.7732(63) 58.64(48)×10−9 −0.09054(47)
3 25 0.971 11.80(49)×10−9 −0.6117(70) 51.75(85)×10−9 −0.07664(62)
4 30 0.968 8.93(22)×10−9 −0.6380(46) 57.84(54)×10−9 −0.119917(57)
5 21 0.989 9.62(32)×10−9 −0.6316(57) 55.77(57)×10−9 −0.10937(74)
6 23 0.926 9.21(31)×10−9 −0.5501(58) 63.92(60)×10−9 −0.098772(59)
B 7 11 0.969 4.3(2.5)×10−11 0.248(99) 2.51(21)×10−8 −0.0640(40)
8 13 0.932 2.9(3.2)×10−9 −0.46(19) 5.88(53)×10−8 −0.0720(40)
9 15 0.971 5.6(1.7)×10−8 −0.900(51) 0.47(12)×10−7 −0.119(18)
10 12 0.9 4.3(1.2)×10−9 −0.476(46) 2.65(47)×10−8 −0.0740(70)
C 11 8 0.999 68.93(79)×10−8 −1.4550(26) 24.49(15)×10−9 −0.1086(54)
12 8 0.999 121.63(68)×10−9 −1.0359(10) 86.51(35)×10−9 −0.123770(20)
13 7 0.999 7.96(11)×10−8 −1.0903(30) 653.53(63)×10−10 −0.10410(10)
14 7 0.999 14.70(11)×10−8 −1.0716(17) 454.06(65)×10−10 −0.10435(15)
15 7 0.999 13.60(11)×10−8 −1.0850(18) 486.23(98)×10−10 −0.09430(30)
16 11 0.989 6.92(43)×10−9 −0.550(12) 0.36(12)×10−7 −0.0715(88)
17 7 0.999 84.40(33)×10−8 −1.4174(10) 1.1(7.9)×10−3 −0.62(33)
18 7 0.999 25.10(26)×10−8 −1.1520(20) 50.70(11)×10−9 −0.10095(30)
19 7 0.996 10.50(33)×10−11 0.2898(61) 3811.14(62)×10−11 −0.048120(10)
D 20 2 1 88(-)×10−11 −0.225(-) – –
21 3 0.895 3.78(14)×10−9 −0.3930(70) – –
22 3 0.804 6.73(72)×10−9 −0.562(20) – –
Parameters A–D were obtained for each individual subject by fitting the curve to the experimental data. For subjects 14–16, only power term
parameters were assessed based on data points obtained >150 days after isotope administration (see text). Uncertainties in the two last
significant digits (1 SD) are given in parentheses.
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better described for subgroups A, B and C (R2=0.90–0.99)
than for subgroup D (R2=0.80–1.00) using nonlinear curve-
fitting techniques. This can be attributed to either the limited
number of data points available and/or the use of Eq. 5 to
describe tracer kinetics for subgroup D, which does not consider
the early phase of tracer excretion (<100 days post-dose).
Selection of the appropriate compartmental model using
population pharmacokinetics
The pharmacokinetic data collected in these 22 subjects for
up to 700 days permit the evaluation and comparison of
several compartmental models for describing Ca distribution
within, and elimination from, the human body. Ca distribu-
tion and excretion is described as a series of compartments
representing Ca pools that exchange with defined Ca transfer
rates k. This analysis considers the urinary 41Ca/40Ca isotope
ratio to be a monitor of the 41Ca/40Ca isotope ratio in
plasma. The process used to find a suitable model started
with the use of a basic compartmental model consisting of
two compartments (Table 4, model 1). The inclusion of a
third compartment resulted in a decrease in the BIC of at
least 255 units, indicating a considerable improvement of the
fit of the 41Ca/40Ca isotope ratio data (Table 4, models 2–6).
Compartment model  p (fixed+random) OF BIC
(1) 8 (4+4) 622.8  642.3
(2) 12 (6+6) 355.2  384.5
(3) 12 (6+6) 355.5  384.8 
(4) 12 (6+6) 358.0  387.3
(5) 12 (6+6) 358.0  387.3 
(6) 12 (6+6) 355.2  386.9 
(7) 16 (8+8) 355.2  394.3
(8) 16 (8+8) 355.1  394.2 
(9) 16 (8+8) 349.3  388.4 
(10) 16 (8+8) 349.0  388.1 
(11) 16 (8+8) 348.3  387.4 
(12) 16 (8+8) 347.8  386.9 
(13) 16 (8+8) 347.8  386.9 
(14) 16 (8+8) 347.2  386.3 
(15) 16 (8+8) 342.7  381.8
(16) 16 (8+8) 341.6  380.7 
(17) 20 (10+10) 347.5  396.4  
Model finding was performed by NONMEM population pharmacokinetic analysis using all data obtained for the 22 subjects in the study.
The BIC-criterion is calculated as the sum of the NONMEM objective function (OF) and number of estimated parameters (p) in the
model multiplied with the log of the number of observations in the study (N=278) (Eq. 3). Model 2 was found to best describe observations
based on the minimum BIC value. For models 15 and 16, a slight reduction of the BIC value by 2.7 to 3.8 units compared with model 2
was observed. However, residual plots for models 15 or 16 did not show any improvement. NRMSE and NME for the differences between
observations and predictions were higher for model 15 (NRMSE: 0.297, NME: 0.021) and model 16 (NMRSE: 0.386, NME: 0.168)
when compared with model 2 (NRMSE: 0.285, NME 0.016).
Table 4 Identification of the model that describes experimental data for urinary 41Ca excretion best
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Since models 2 and 3 exhibited a lower BIC than the other
three-compartment models tested (Table 4, models 4–6), we
selected these two models for further evaluation. Both
models exhibit comparable BIC values (384.5 and 384.8),
indicating equally good descriptions of the data. Further-
more, the residual plots and the variability estimates were
comparable between both models, with model 2 a sequential
model and model 3 a Y-type model. Many recent models
[35–37] use a series model, although various authors [25,
38] have pointed out the equivalence of the various
branching schemes, concluding that the choice of model
architecture is ultimately heuristic.
In addition, we tested several four-compartment models
which appeared to be physiologically meaningful (Table 4,
models 7–16). However, most of these models did not
reduce the BIC any further when compared with the
proposed three-compartment model 2. Slight reductions in
the BIC by 2.7 to 3.8 units were observed for models 15 and
16. However, no visual improvement of the fits could be
detected. Furthermore, the residual plots did not show any
improvement from model 2 to model 15 or 16. This small
difference was confirmed by slight increases in NRMSE and
NME for the differences between observations and predic-
tions for model 15 (NRMSE: 0.297, NME: 0.021) and
model 16 (NMRSE: 0.386, NME: 0.168) in comparison with
model 2 (NRMSE: 0.285, NME 0.016). We thus concluded
that none of the four-compartment models described the
population data better than the proposed three-compartment
model 2 in Table 4. Furthermore, a five-compartment model
(Table 4, model 18) was tested which also did not improve
the BIC. We thus concluded that the sequential three-
compartment model 2 in Table 4 best describes the data
over the time periods represented.
Description of the model
The final model, given schematically in Fig. 3, is defined
by the following series of equations defining the transfer
rates (k12, k21, k23, k32) between the three compartments, the
elimination rate (k10) from compartment 1 and the volume
of compartment 1 (V1) using a series of fixed (θ1–6) and
random (η1–4) effect parameters:
k12 ¼ q1  eh1 ð6Þ
k21 ¼ q2  eh2 ð7Þ
k23 ¼ q3  eh3 ð8Þ
k32 ¼ q4  eh4 ð9Þ
k10 ¼ q5  eh5 ð10Þ
V1 ¼ q6  eh6 ð11Þ
The fixed effect parameters are common to all individ-
uals, whereas each individual has its own random effect
parameters. Since each of the random effect parameters
exhibit a mean of 0, the θ values represent the mean
parameters of the population, whereas their variability is
estimated as being the variances of the random effect
parameters η. The initial statistical model included an
exponential error and an additive error term accounting
for intra-individual variability. It was found that the
additive error term became negligible during analysis and
it was therefore excluded (data not shown). Figure 4 gives
the population prediction and the data for all individuals,
and Table 5 lists all parameter estimates.
It is important to reiterate that the compartments may not
correspond directly to anatomic spaces but best describe the
41Ca tracer kinetics: the tracer enters the central (i.e., the
dosing) compartment (compartment 1), it is transferred to a
fast exchanging pool (compartment 2), from where it is
transferred to a slowly exchanging Ca pool within the body
(compartment 3), probably predominantly located in bone
(see Fig. 3). Transfer rates obtained for this model refer to
long-term 41Ca tracer kinetics. Conventional techniques
used to determine tracee (i.e., natural Ca) kinetics from
tracer data are usually performed over 1–2 weeks. This
requires the assumption of a steady state (zero net Ca
balance) for body Ca, which can hold for short-term
studies, but may not hold for our experiment in which
postmenopausal women were followed up to two years
post-dosing.
K12 K23
K32K21
K10
C1 C2 C3
Fig. 3 Compartmental model that was found to best describe the
observed 41Ca tracer kinetics. Compartments can, but do not have to,
correspond directly to anatomic spaces. The 41Ca tracer enters the
central compartment, to which the dose was administrated (compart-
ment C1), and is transferred to a fast exchanging pool (compartment
C2), from where it is transferred to a slowly exchanging Ca pool in the
body (compartment C3), probably located in bone
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Combined power law/exponential versus pharmacokinetic
compartmental analysis
For direct comparison purposes, the relative deviations
between predicted and measured values for the power/
exponential analysis and the compartmental model are
presented in Fig. 5 as relative differences in percent for
the six subjects of subgroup A at each sampling time point
during the 700-day labeling period. Mean deviations of
measurements from predictions for the noncompartmental
approach were (−10±7)% for negative and (15±12)% for
positive divergence, totaling (−1±13)%. For the compart-
mental modeling approach, relative differences between
modeled data and 41Ca measurements were (−6±5)% for
negative and (−6±4)% for positive divergence at a
combined divergence of (0±7)%. This clearly demonstrates
the advantages of the compartmental analysis approach. For
this technique, relative differences between measured and
modeled data points were found to be smaller and more
balanced between negative and positive divergence, indi-
cating a better description of the data than obtained by the
modeled curve. Fits based on the use of a combined
exponential/power law to describe urinary tracer excretion
showed substantially higher deviations, which were fairly
unbalanced between negative and positive divergence.
Positive and negative divergences between measured and
predicted data points for compartmental analysis were
symmetric during the 700-day labeling period, and signif-
icantly smaller. Long-term variability of divergence (1 SD)
was 4% from day 150 after isotope administration, which is
higher than the short-term variability of the 41Ca signal
(∼3%), determined over five days. This translates into a
detection limit for a shift in the 41Ca signal of 12% when a
single urine sample is analyzed at the end of the
intervention period.
Use of 41Ca as a tool to assess the impact of interventions
on bone health
Start of a possible intervention
41Ca may provide a powerful tool for directly monitoring
changes in bone metabolism in response to an intervention
to a sensitivity that is expected to surpass the power of
conventional techniques. For these applications, however,
meaningful information can only be obtained when urinary
41Ca originates mainly from bone. To identify this stage
within the labeling process, changes in 41Ca distribution
between the compartments with time were calculated using
the population parameters in Eqs. 5–11 (see Fig. 6).
Following administration, the tracer is quickly transferred
from the central compartment (C1) to the fast exchanging
compartment (C2). A maximum amount of the tracer in C2
can be found 20–30 days post-dosing. After that, 41Ca is
successively transferred from the fast exchanging compart-
ment to the slowly exchanging bone compartment (C3) (see
Fig. 3). The maximum amount of the 41Ca in this
compartment is reached after 150–250 days. While changes
in bone formation and resorption can be identified, in
principle, by monitoring urinary 41Ca excretion over the
first few weeks post-dosing, a more reliable assessment of
the effect of intervention is possible after ∼150 days post-
dosing, when excreted tracer mainly originates from bone.
We propose that an intervention can be started after the
amount of 41Ca in compartment 3 (see Fig. 6) has reached a
maximum, i.e., at least 150 days after 41Ca administration,
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Fig. 4 Kinetics of urinary 41Ca
excretion in all subjects (open
circles). Datasets of two repre-
sentative subjects (ID 20,
squares, and 22, triangles) were
described by curves obtained
from the computed population
prediction (NONMEM) for the
sequential three-compartmental
model illustrated in Fig. 3. The
41Ca urinary excretion data for
all subjects are shown in the
inset
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Fig. 5 Relative differences (%)
between measured and calculat-
ed 41Ca/40Ca isotope ratios, as
obtained by applying a com-
bined exponential/power law
(open circles) or population
prediction (NONMEM) of the
sequential three-compartmental
model (filled circles) to describe
the run of the curve for urinary
41Ca excretion. Data are pre-
sented for the six subjects of
subgroup A, in which urinary
41Ca excretion was monitored
up to 700 days after a single oral
dose of 41Ca (day 0)
Table 5 Parameters describing the changes in urinary 41Ca/40Ca isotope ratios with time, obtained based on a sequential three-compartment
model as illustrated in Fig. 3
ID K10 K12 K21 K23 K32 V1
Population parameters Estimate 0.065 0.041 0.015 0.020 0.0041 65.5
SE (%) 19.7 8.6 50.6 8.3 20.0 14.7
Inter-individual variability (*) % Estimate 0.018 0.058 0.105 0.014 0.0503 0.01
SE (%) 0.1 0.1 0.8 0.2 0.3 0.1
Individual parameters 1 0.065 0.050 0.012 0.019 0.0033 67.1
2 0.071 0.037 0.017 0.019 0.0048 64.8
3 0.059 0.041 0.014 0.019 0.0046 66.0
4 0.076 0.059 0.010 0.021 0.0045 69.3
5 0.075 0.049 0.012 0.020 0.0051 70.5
6 0.057 0.060 0.013 0.021 0.0036 60.2
7 0.078 0.047 0.012 0.020 0.0039 72.5
8 0.067 0.029 0.021 0.022 0.0047 66.6
9 0.076 0.054 0.015 0.018 0.0039 57.1
10 0.071 0.054 0.011 0.022 0.0049 68.2
11 0.064 0.041 0.017 0.019 0.0037 65.5
12 0.056 0.052 0.012 0.020 0.0053 61.0
13 0.071 0.035 0.012 0.020 0.0039 65.0
14 0.060 0.050 0.016 0.019 0.0051 63.0
15 0.062 0.040 0.015 0.019 0.0044 63.7
16 0.066 0.042 0.014 0.021 0.0048 66.2
17 0.058 0.039 0.019 0.019 0.0039 62.3
18 0.056 0.042 0.017 0.019 0.0048 60.8
19 0.055 0.034 0.028 0.018 0.0034 70.0
20 0.071 0.039 0.014 0.021 0.0039 67.3
21 0.061 0.046 0.016 0.020 0.0049 63.2
22 0.066 0.042 0.015 0.020 0.0042 65.7
(*) Intra-individual variability: 9.6±4.5 [% estimate±SE (%)]
Individual parameters (mean ± SE) and population parameters, including inter-individual and intra-individual variability, are given for each
transfer rate kij in fractions per day and for the volume term V1 in liters.
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when the internal pools have reached stable equilibrium and
the excreta constitute a steady but small loss. After this, the
tracer signal would be expected to reflect bone resorption
and accretion processes. Due to the activity of osteoclasts
(cells specialized for bone resorption), 41Ca is successively
resorbed from the bone matrix and transferred to plasma. It
is partly excreted in urine and partly reincorporated into
bone matrix by remineralization in the bone accretion
process. Both processes determine the changes in the
amount of 41Ca circulating in plasma, which can be
monitored via the 41Ca/40Ca isotope ratio in urine.
Identifying the effect of intervention on bone health using
41Ca
To evaluate the effect of intervention on bone resorption
and accretion, the specific excretion pattern of the tracer
may serve as a fixed index from which changes are
measured. An intervention which affects bone resorption
or formation will induce a shift in the urinary 41Ca/40Ca
isotope ratio (see Fig. 1).
The effect of a possible intervention can be evaluated by
calculating the relative difference between the actual
urinary 41Ca/40Ca isotope ratios during an intervention
and their values derived from the extrapolated run of the
labeling curve as the reference. This requires a proper
mathematical description of the labeling curve that allows
for extrapolation to any time point during the intervention.
In order to evaluate how well urinary 41Ca/40Ca isotope
ratios obtained for the labeling phase can be extrapolated to
later time points, labeling curves were computed for
assumed labeling periods of 200, 300, 400 and 500 days,
respectively, based on measured 41Ca data for the subjects
in subgroup A. For these subjects, data points from up to
700 days after dose administration were available, which
could be used to model a maximum labeling interval of
500 days and a maximum duration of the subsequent
intervention period of 180 days. To assess the predictive
power of the different labeling intervals, computed labeling
curves for the different labeling periods were extrapolated
to day 90 and day 180 of an assumed intervention and
compared with the actual measurements at the same time
points. For the evaluation, relative differences between
measured and calculated data points at day 90 and day 180
of the intervention were assessed in each individual subject
for the different labeling periods (200, 300, 400 and
500 days, respectively), see Table 6. Results indicate that
the accuracy of the prediction varies with the length of the
labeling interval. In general, relative differences between
the measured urinary 41Ca/40Ca isotope ratio and its
predicted value were larger at day 180 when compared to
those for day 90 of the assumed intervention period. As can
be seen from Table 6, relative differences between
measured and extrapolated 41Ca/40Ca isotope ratios were
larger when the run of the labeling curve was assessed by
power law/exponential analysis techniques. This clearly
shows that the compartmental modeling approach permits
better prediction of the run of the labeling curve and,
therefore, is preferable when attempting to identify the
effect of an intervention on the urinary 41Ca signal. In any
case, predicted 41Ca/40Ca isotope ratios were significantly
lower than the actual 41Ca/40Ca isotope ratios in urine.
Average offsets were on the order of 10% at day 90 of the
intervention and 20% at day 180 using the compartmental
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41Ca distribution with time be-
tween the three compartments
(C1, C2, C3) (see Fig. 3), as
identified by population predic-
tion (NONMEM) of the se-
quential three-compartmental
model for the data from all
subjects
1600 Anal Bioanal Chem (2006) 386:1587–1602
approach, and were even higher for the noncompartmental
technique. Using compartmental modeling techniques, the
between-subject variability of the offset (1 SD) was on the
order of ±10%, irrespective of the length of the labeling and
the intervention period. This observation can be explained
by imperfections in the underlying compartment model and
small changes in Ca metabolism in the individual subjects
that may have occurred over the observation period due to
changes in diet, lifestyle or other factors.
The limitation of the approach described can be
overcome by identifying induced changes in Ca transfer
rates in the chosen compartment model itself. This can be
done by including one or more additional fixed effect
parameters θ in the underlying equations describing the
effect of the intervention on one (or more) transfer rates
between compartments. As an example, Eq. 7 for the
chosen three-compartment model must be modified as
follows for an assumed effect of the intervention on the
transfer rate k21 (see Fig. 3); θ7 is an additional parameter
describing the effect of the intervention on the transfer rate.
k21 ¼ q2  1 T  q7ð Þ  eh2 ð12Þ
A binary variable T must be included for computational
reasons, to indicate the time point from which the effect
becomes effective, i.e., T=0 during the labeling period and
T=1 during the intervention. Obviously, the transfer rates
that are affected by the intervention are unknown a priori. A
new model-finding procedure must be carried out in which
all possible effects on the various transfer rates in the
compartment model are tested in order to identify which of
the modified models describe the experimental data best.
Finally, a 95% confidence interval can be estimated for the
additional parameter(s) using a likelihood ratio profile in
order to explore whether the effect on one or more transfer
rates is statistically significant [39]. Although this approach
is more complex and requires extensive computing, model
misspecifications are accounted for by using the same basic
compartment model to evaluate data during the labeling
period as well as the intervention period. Furthermore,
additional information is gained because the effects of the
intervention on the individual Ca compartments can be
assessed.
Conclusion
We have successfully demonstrated that bone Ca can be
labeled with the long-lived radioisotope 41Ca, and that
urinary 41Ca excretion can be followed over periods of years
using AMS, the most sensitive technique for isotopic analysis
at the ultratrace level. RIMS, an alternative analytical
approach to 41Ca analysis, is currently less sensitive and
requires higher 41Ca enrichments/doses. However, this
disadvantage is counterbalanced by its potential to make this
technique more accessible to the research community.
Although the RIMS instrument used is still a prototype and
not commercially available, it is a tabletop instrument which
can be manufactured at substantially lower costs than AMS.
Using the series of certified 41Ca isotope reference materials
produced especially for this application, it was possible to
calibrate both techniques against each other [15], allowing
the parallel use of both AMS and RIMS 41Ca analysis.
After administration of the isotope, it takes about 150–
250 days until the maximum amount of tracer is
incorporated into bone matrix. From this time point
onward, the urinary 41Ca/40Ca isotope ratio can be used to
assess the effect of an intervention on bone. Using
population compartmental modeling techniques, the urinary
41Ca excretion pattern can be described by a sequential
three-compartmental model, which was found to be the
preferred method/model for data evaluation. Besides giving a
better description of urinary 41Ca excretion, it allows the
effect of an intervention to be evaluated by identifying
changes in transfer rates of the tracer.
This technique could potentially be used to evaluate the
influence of diet and lifestyle on Ca metabolism in bone, and
Table 6 Identification of the predictive power of exponential/power law and compartmental modeling when used to describe urinary 41Ca
excretion
Labeling period Compartmental model Exponential/power law model
90 days prediction 180 days prediction 90 days prediction 180 days prediction
200 days −4±7 −18 ±11 37±21 79±44
300 days −14±8 −29±14 39±23 75±44
400 days 5±14 −12 ±16 14±21 4 ±35
500 days −16±10 −20±6 35 ±40 40 ±42
Labeling curves were modeled using the data obtained for subject subgroup A (n=6) for assumed labeling intervals of 200, 300, 400 and
500 days, respectively. Curves were extrapolated to day 90 and day 180 as possible endpoints of a subsequent intervention. Data are presented
as the relative differences in % of the measured from the calculated 41 Ca/40 Ca isotope ratios around day 90 and day 180 from the end of
the assumed labeling interval. Differences were calculated for the actual time points for which data were available (±30 days around day 90
and day 180 of the intervention interval) and grouped accordingly.
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to develop better strategies for osteoporosis prevention. The
potential of the technique to assess the effect of interventions
on bone health is currently under investigation.
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